Experimental cancer drug BGB-3245 studied in early trial

NCT ID NCT04249843

Terminated Disease control Sponsor: MapKure, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study tested an experimental drug called BGB-3245 (brimarafenib) in 109 people with advanced solid tumors that had not responded to standard treatments. The drug is designed to block certain proteins that help cancer grow. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated early, but it gathered important safety and dosing information.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGB-3245 (brimarafenib), a drug taken by mouth that targets certain cancer-related proteins
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific genetic mutations.
What could go wrong: This was a very early (Phase 1) trial that was terminated, so results are limited. The drug may not shrink tumors or may cause side effects, and it is unclear if it will work for most patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-RAF MUTATION-RELATED TUMORS SOLID TUMOR

Contacts and locations

Locations

Blacktown Hospital

Blacktown, New South Wales, 2148, Australia
Cedars Sinai Medical Center

Beverly Hills, California, 90212, United States
MD Anderson

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
One Clinical Research

Nedlands, Perth, 6009, Australia
Peter MacCallum Cancer Centre

Melbourne, Victoria, 2010, Australia
The Kinghorn Cancer Centre, St Vincent Hospital Sydney

Sydney, New South Wales, 2010, Australia
University of Virginia Comprehensive Cancer Centre

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.